Dr Kaufman presents results at AACR 2017 of a trial administering avelumab to patients with advanced Merkel cell carcinoma who had not responded to chemotherapy. Slides from this presentation are available here, and you can read more about the results...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2osTpBu
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Ich konzipiere den in London wirkende Schweizer Maler Heinrich Füssli (Henry Fuseli, 1741-1825) als Klassizist, die eine neue Sichtweise der...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oz7Jcs via IFTTT
-
A new study among more than 1000 colorectal cancer patients at Dana-Farber Cancer Institute has revealed that a surprising number of patient...
-
Publication date: August 2017 Source: International Journal of Biological Macromolecules, Volume 101 Author(s): Toiba Majeed, Idrees Ahme...
-
I'm asked by all of my doctoral students at some point during their writing to give them good dissertation examples. I'm not complai...
-
Vol.24 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1RxFyR3 via IFTTT
-
Write to your politicians, national or local, for free. Over 200,000 messages sent last year. from #AlexandrosSfakianakis via Alexandros G...
-
In utero exposure to radiation and haematological malignancies: pooled analysis of Southern Urals cohorts British Journal of Cancer 116, 12...
-
Purpose: Using gene-disrupted allogeneic T cells as universal effector cells provides an alternative and potentially improves current chime...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου